Obligatory Role for B Cells in the Development of Angiotensin II-Dependent Hypertension.
Clinical hypertension is associated with raised serum IgG antibodies. However, whether antibodies are causative agents in hypertension remains unknown. We investigated whether hypertension in mice is associated with B-cell activation and IgG production and moreover whether B-cell/IgG deficiency affords protection against hypertension and vascular remodeling. Angiotensin II (Ang II) infusion (0.7 mg/kg per day; 28 days) was associated with (1) a 25% increase in the proportion of splenic B cells expressing the activation marker CD86, (2) an 80% increase in splenic plasma cell numbers, (3) a 500% increase in circulating IgG, and (4) marked IgG accumulation in the aortic adventitia. In B-cell-activating factor receptor-deficient (BAFF-R(-/-)) mice, which lack mature B cells, there was no evidence of Ang II-induced increases in serum IgG. Furthermore, the hypertensive response to Ang II was attenuated in BAFF-R(-/-) (Δ30±4 mm Hg) relative to wild-type (Δ41±5 mm Hg) mice, and this response was rescued by B-cell transfer. BAFF-R(-/-) mice displayed reduced IgG accumulation in the aorta, which was associated with 80% fewer aortic macrophages and a 70% reduction in transforming growth factor-β expression. BAFF-R(-/-) mice were also protected from Ang II-induced collagen deposition and aortic stiffening (assessed by pulse wave velocity analysis). Finally, like BAFF-R deficiency, pharmacological depletion of B cells with an anti-CD20 antibody attenuated Ang II-induced hypertension by ≈35%. Hence, these studies demonstrate that B cells/IgGs are crucial for the development of Ang II-induced hypertension and vessel remodeling in mice. Thus, B-cell-targeted therapies-currently used for autoimmune diseases-may hold promise as future treatments for hypertension.
From the Cardiovascular Disease Program, Biomedicine Discovery Institute (C.T.C., C.G.S., M.L., D.F., M.M.K., H.D., H.A.K., S.M.K., C.V.L., A.V., C.S.S., G.R.D.), Department of Pharmacology (C.T.C., C.G.S., M.L., D.F., H.D., H.A.K., S.M.K., C.V.L., A.V., C.S.S., G.R.D.), Department of Surgery, Monash Health (C.G.S., G.R.D.), Department of Physiology (M.M.K.), Australian Regenerative Medicine Institute (E.S.), and Centre for Inflammatory Diseases, Department of Medicine, Southern Clinical School (P.T., B.-H.T.), Monash University, Clayton Victoria, Australia; Atherothrombosis and Vascular Laboratory (K.P.) and Vascular Biology and Atherosclerosis Laboratory (T.S.K., A.B.), Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia; British Heart Foundation Centre for Excellence, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom (T.J.G.); and Department of Internal Medicine, Jagiellonian University, Cracow, Poland (T.J.G).
Christopher T
CT
Chan
From the Cardiovascular Disease Program, Biomedicine Discovery Institute (C.T.C., C.G.S., M.L., D.F., M.M.K., H.D., H.A.K., S.M.K., C.V.L., A.V., C.S.S., G.R.D.), Department of Pharmacology (C.T.C., C.G.S., M.L., D.F., H.D., H.A.K., S.M.K., C.V.L., A.V., C.S.S., G.R.D.), Department of Surgery, Monash Health (C.G.S., G.R.D.), Department of Physiology (M.M.K.), Australian Regenerative Medicine Institute (E.S.), and Centre for Inflammatory Diseases, Department of Medicine, Southern Clinical School (P.T., B.-H.T.), Monash University, Clayton Victoria, Australia; Atherothrombosis and Vascular Laboratory (K.P.) and Vascular Biology and Atherosclerosis Laboratory (T.S.K., A.B.), Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia; British Heart Foundation Centre for Excellence, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom (T.J.G.); and Department of Internal Medicine, Jagiellonian University, Cracow, Poland (T.J.G).
Christopher G
CG
Sobey
From the Cardiovascular Disease Program, Biomedicine Discovery Institute (C.T.C., C.G.S., M.L., D.F., M.M.K., H.D., H.A.K., S.M.K., C.V.L., A.V., C.S.S., G.R.D.), Department of Pharmacology (C.T.C., C.G.S., M.L., D.F., H.D., H.A.K., S.M.K., C.V.L., A.V., C.S.S., G.R.D.), Department of Surgery, Monash Health (C.G.S., G.R.D.), Department of Physiology (M.M.K.), Australian Regenerative Medicine Institute (E.S.), and Centre for Inflammatory Diseases, Department of Medicine, Southern Clinical School (P.T., B.-H.T.), Monash University, Clayton Victoria, Australia; Atherothrombosis and Vascular Laboratory (K.P.) and Vascular Biology and Atherosclerosis Laboratory (T.S.K., A.B.), Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia; British Heart Foundation Centre for Excellence, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom (T.J.G.); and Department of Internal Medicine, Jagiellonian University, Cracow, Poland (T.J.G).
Maggie
M
Lieu
From the Cardiovascular Disease Program, Biomedicine Discovery Institute (C.T.C., C.G.S., M.L., D.F., M.M.K., H.D., H.A.K., S.M.K., C.V.L., A.V., C.S.S., G.R.D.), Department of Pharmacology (C.T.C., C.G.S., M.L., D.F., H.D., H.A.K., S.M.K., C.V.L., A.V., C.S.S., G.R.D.), Department of Surgery, Monash Health (C.G.S., G.R.D.), Department of Physiology (M.M.K.), Australian Regenerative Medicine Institute (E.S.), and Centre for Inflammatory Diseases, Department of Medicine, Southern Clinical School (P.T., B.-H.T.), Monash University, Clayton Victoria, Australia; Atherothrombosis and Vascular Laboratory (K.P.) and Vascular Biology and Atherosclerosis Laboratory (T.S.K., A.B.), Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia; British Heart Foundation Centre for Excellence, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom (T.J.G.); and Department of Internal Medicine, Jagiellonian University, Cracow, Poland (T.J.G).
Dorota
D
Ferens
From the Cardiovascular Disease Program, Biomedicine Discovery Institute (C.T.C., C.G.S., M.L., D.F., M.M.K., H.D., H.A.K., S.M.K., C.V.L., A.V., C.S.S., G.R.D.), Department of Pharmacology (C.T.C., C.G.S., M.L., D.F., H.D., H.A.K., S.M.K., C.V.L., A.V., C.S.S., G.R.D.), Department of Surgery, Monash Health (C.G.S., G.R.D.), Department of Physiology (M.M.K.), Australian Regenerative Medicine Institute (E.S.), and Centre for Inflammatory Diseases, Department of Medicine, Southern Clinical School (P.T., B.-H.T.), Monash University, Clayton Victoria, Australia; Atherothrombosis and Vascular Laboratory (K.P.) and Vascular Biology and Atherosclerosis Laboratory (T.S.K., A.B.), Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia; British Heart Foundation Centre for Excellence, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom (T.J.G.); and Department of Internal Medicine, Jagiellonian University, Cracow, Poland (T.J.G).
Michelle M
MM
Kett
From the Cardiovascular Disease Program, Biomedicine Discovery Institute (C.T.C., C.G.S., M.L., D.F., M.M.K., H.D., H.A.K., S.M.K., C.V.L., A.V., C.S.S., G.R.D.), Department of Pharmacology (C.T.C., C.G.S., M.L., D.F., H.D., H.A.K., S.M.K., C.V.L., A.V., C.S.S., G.R.D.), Department of Surgery, Monash Health (C.G.S., G.R.D.), Department of Physiology (M.M.K.), Australian Regenerative Medicine Institute (E.S.), and Centre for Inflammatory Diseases, Department of Medicine, Southern Clinical School (P.T., B.-H.T.), Monash University, Clayton Victoria, Australia; Atherothrombosis and Vascular Laboratory (K.P.) and Vascular Biology and Atherosclerosis Laboratory (T.S.K., A.B.), Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia; British Heart Foundation Centre for Excellence, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom (T.J.G.); and Department of Internal Medicine, Jagiellonian University, Cracow, Poland (T.J.G).
Henry
H
Diep
From the Cardiovascular Disease Program, Biomedicine Discovery Institute (C.T.C., C.G.S., M.L., D.F., M.M.K., H.D., H.A.K., S.M.K., C.V.L., A.V., C.S.S., G.R.D.), Department of Pharmacology (C.T.C., C.G.S., M.L., D.F., H.D., H.A.K., S.M.K., C.V.L., A.V., C.S.S., G.R.D.), Department of Surgery, Monash Health (C.G.S., G.R.D.), Department of Physiology (M.M.K.), Australian Regenerative Medicine Institute (E.S.), and Centre for Inflammatory Diseases, Department of Medicine, Southern Clinical School (P.T., B.-H.T.), Monash University, Clayton Victoria, Australia; Atherothrombosis and Vascular Laboratory (K.P.) and Vascular Biology and Atherosclerosis Laboratory (T.S.K., A.B.), Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia; British Heart Foundation Centre for Excellence, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom (T.J.G.); and Department of Internal Medicine, Jagiellonian University, Cracow, Poland (T.J.G).
Hyun Ah
HA
Kim
From the Cardiovascular Disease Program, Biomedicine Discovery Institute (C.T.C., C.G.S., M.L., D.F., M.M.K., H.D., H.A.K., S.M.K., C.V.L., A.V., C.S.S., G.R.D.), Department of Pharmacology (C.T.C., C.G.S., M.L., D.F., H.D., H.A.K., S.M.K., C.V.L., A.V., C.S.S., G.R.D.), Department of Surgery, Monash Health (C.G.S., G.R.D.), Department of Physiology (M.M.K.), Australian Regenerative Medicine Institute (E.S.), and Centre for Inflammatory Diseases, Department of Medicine, Southern Clinical School (P.T., B.-H.T.), Monash University, Clayton Victoria, Australia; Atherothrombosis and Vascular Laboratory (K.P.) and Vascular Biology and Atherosclerosis Laboratory (T.S.K., A.B.), Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia; British Heart Foundation Centre for Excellence, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom (T.J.G.); and Department of Internal Medicine, Jagiellonian University, Cracow, Poland (T.J.G).
Shalini M
SM
Krishnan
From the Cardiovascular Disease Program, Biomedicine Discovery Institute (C.T.C., C.G.S., M.L., D.F., M.M.K., H.D., H.A.K., S.M.K., C.V.L., A.V., C.S.S., G.R.D.), Department of Pharmacology (C.T.C., C.G.S., M.L., D.F., H.D., H.A.K., S.M.K., C.V.L., A.V., C.S.S., G.R.D.), Department of Surgery, Monash Health (C.G.S., G.R.D.), Department of Physiology (M.M.K.), Australian Regenerative Medicine Institute (E.S.), and Centre for Inflammatory Diseases, Department of Medicine, Southern Clinical School (P.T., B.-H.T.), Monash University, Clayton Victoria, Australia; Atherothrombosis and Vascular Laboratory (K.P.) and Vascular Biology and Atherosclerosis Laboratory (T.S.K., A.B.), Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia; British Heart Foundation Centre for Excellence, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom (T.J.G.); and Department of Internal Medicine, Jagiellonian University, Cracow, Poland (T.J.G).
Caitlin V
CV
Lewis
From the Cardiovascular Disease Program, Biomedicine Discovery Institute (C.T.C., C.G.S., M.L., D.F., M.M.K., H.D., H.A.K., S.M.K., C.V.L., A.V., C.S.S., G.R.D.), Department of Pharmacology (C.T.C., C.G.S., M.L., D.F., H.D., H.A.K., S.M.K., C.V.L., A.V., C.S.S., G.R.D.), Department of Surgery, Monash Health (C.G.S., G.R.D.), Department of Physiology (M.M.K.), Australian Regenerative Medicine Institute (E.S.), and Centre for Inflammatory Diseases, Department of Medicine, Southern Clinical School (P.T., B.-H.T.), Monash University, Clayton Victoria, Australia; Atherothrombosis and Vascular Laboratory (K.P.) and Vascular Biology and Atherosclerosis Laboratory (T.S.K., A.B.), Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia; British Heart Foundation Centre for Excellence, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom (T.J.G.); and Department of Internal Medicine, Jagiellonian University, Cracow, Poland (T.J.G).
Ekaterina
E
Salimova
From the Cardiovascular Disease Program, Biomedicine Discovery Institute (C.T.C., C.G.S., M.L., D.F., M.M.K., H.D., H.A.K., S.M.K., C.V.L., A.V., C.S.S., G.R.D.), Department of Pharmacology (C.T.C., C.G.S., M.L., D.F., H.D., H.A.K., S.M.K., C.V.L., A.V., C.S.S., G.R.D.), Department of Surgery, Monash Health (C.G.S., G.R.D.), Department of Physiology (M.M.K.), Australian Regenerative Medicine Institute (E.S.), and Centre for Inflammatory Diseases, Department of Medicine, Southern Clinical School (P.T., B.-H.T.), Monash University, Clayton Victoria, Australia; Atherothrombosis and Vascular Laboratory (K.P.) and Vascular Biology and Atherosclerosis Laboratory (T.S.K., A.B.), Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia; British Heart Foundation Centre for Excellence, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom (T.J.G.); and Department of Internal Medicine, Jagiellonian University, Cracow, Poland (T.J.G).
Peter
P
Tipping
From the Cardiovascular Disease Program, Biomedicine Discovery Institute (C.T.C., C.G.S., M.L., D.F., M.M.K., H.D., H.A.K., S.M.K., C.V.L., A.V., C.S.S., G.R.D.), Department of Pharmacology (C.T.C., C.G.S., M.L., D.F., H.D., H.A.K., S.M.K., C.V.L., A.V., C.S.S., G.R.D.), Department of Surgery, Monash Health (C.G.S., G.R.D.), Department of Physiology (M.M.K.), Australian Regenerative Medicine Institute (E.S.), and Centre for Inflammatory Diseases, Department of Medicine, Southern Clinical School (P.T., B.-H.T.), Monash University, Clayton Victoria, Australia; Atherothrombosis and Vascular Laboratory (K.P.) and Vascular Biology and Atherosclerosis Laboratory (T.S.K., A.B.), Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia; British Heart Foundation Centre for Excellence, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom (T.J.G.); and Department of Internal Medicine, Jagiellonian University, Cracow, Poland (T.J.G).
Antony
A
Vinh
From the Cardiovascular Disease Program, Biomedicine Discovery Institute (C.T.C., C.G.S., M.L., D.F., M.M.K., H.D., H.A.K., S.M.K., C.V.L., A.V., C.S.S., G.R.D.), Department of Pharmacology (C.T.C., C.G.S., M.L., D.F., H.D., H.A.K., S.M.K., C.V.L., A.V., C.S.S., G.R.D.), Department of Surgery, Monash Health (C.G.S., G.R.D.), Department of Physiology (M.M.K.), Australian Regenerative Medicine Institute (E.S.), and Centre for Inflammatory Diseases, Department of Medicine, Southern Clinical School (P.T., B.-H.T.), Monash University, Clayton Victoria, Australia; Atherothrombosis and Vascular Laboratory (K.P.) and Vascular Biology and Atherosclerosis Laboratory (T.S.K., A.B.), Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia; British Heart Foundation Centre for Excellence, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom (T.J.G.); and Department of Internal Medicine, Jagiellonian University, Cracow, Poland (T.J.G).
Chrishan S
CS
Samuel
From the Cardiovascular Disease Program, Biomedicine Discovery Institute (C.T.C., C.G.S., M.L., D.F., M.M.K., H.D., H.A.K., S.M.K., C.V.L., A.V., C.S.S., G.R.D.), Department of Pharmacology (C.T.C., C.G.S., M.L., D.F., H.D., H.A.K., S.M.K., C.V.L., A.V., C.S.S., G.R.D.), Department of Surgery, Monash Health (C.G.S., G.R.D.), Department of Physiology (M.M.K.), Australian Regenerative Medicine Institute (E.S.), and Centre for Inflammatory Diseases, Department of Medicine, Southern Clinical School (P.T., B.-H.T.), Monash University, Clayton Victoria, Australia; Atherothrombosis and Vascular Laboratory (K.P.) and Vascular Biology and Atherosclerosis Laboratory (T.S.K., A.B.), Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia; British Heart Foundation Centre for Excellence, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom (T.J.G.); and Department of Internal Medicine, Jagiellonian University, Cracow, Poland (T.J.G).
Karlheinz
K
Peter
From the Cardiovascular Disease Program, Biomedicine Discovery Institute (C.T.C., C.G.S., M.L., D.F., M.M.K., H.D., H.A.K., S.M.K., C.V.L., A.V., C.S.S., G.R.D.), Department of Pharmacology (C.T.C., C.G.S., M.L., D.F., H.D., H.A.K., S.M.K., C.V.L., A.V., C.S.S., G.R.D.), Department of Surgery, Monash Health (C.G.S., G.R.D.), Department of Physiology (M.M.K.), Australian Regenerative Medicine Institute (E.S.), and Centre for Inflammatory Diseases, Department of Medicine, Southern Clinical School (P.T., B.-H.T.), Monash University, Clayton Victoria, Australia; Atherothrombosis and Vascular Laboratory (K.P.) and Vascular Biology and Atherosclerosis Laboratory (T.S.K., A.B.), Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia; British Heart Foundation Centre for Excellence, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom (T.J.G.); and Department of Internal Medicine, Jagiellonian University, Cracow, Poland (T.J.G).
Tomasz J
TJ
Guzik
From the Cardiovascular Disease Program, Biomedicine Discovery Institute (C.T.C., C.G.S., M.L., D.F., M.M.K., H.D., H.A.K., S.M.K., C.V.L., A.V., C.S.S., G.R.D.), Department of Pharmacology (C.T.C., C.G.S., M.L., D.F., H.D., H.A.K., S.M.K., C.V.L., A.V., C.S.S., G.R.D.), Department of Surgery, Monash Health (C.G.S., G.R.D.), Department of Physiology (M.M.K.), Australian Regenerative Medicine Institute (E.S.), and Centre for Inflammatory Diseases, Department of Medicine, Southern Clinical School (P.T., B.-H.T.), Monash University, Clayton Victoria, Australia; Atherothrombosis and Vascular Laboratory (K.P.) and Vascular Biology and Atherosclerosis Laboratory (T.S.K., A.B.), Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia; British Heart Foundation Centre for Excellence, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom (T.J.G.); and Department of Internal Medicine, Jagiellonian University, Cracow, Poland (T.J.G).
Tin S
TS
Kyaw
From the Cardiovascular Disease Program, Biomedicine Discovery Institute (C.T.C., C.G.S., M.L., D.F., M.M.K., H.D., H.A.K., S.M.K., C.V.L., A.V., C.S.S., G.R.D.), Department of Pharmacology (C.T.C., C.G.S., M.L., D.F., H.D., H.A.K., S.M.K., C.V.L., A.V., C.S.S., G.R.D.), Department of Surgery, Monash Health (C.G.S., G.R.D.), Department of Physiology (M.M.K.), Australian Regenerative Medicine Institute (E.S.), and Centre for Inflammatory Diseases, Department of Medicine, Southern Clinical School (P.T., B.-H.T.), Monash University, Clayton Victoria, Australia; Atherothrombosis and Vascular Laboratory (K.P.) and Vascular Biology and Atherosclerosis Laboratory (T.S.K., A.B.), Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia; British Heart Foundation Centre for Excellence, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom (T.J.G.); and Department of Internal Medicine, Jagiellonian University, Cracow, Poland (T.J.G).
Ban-Hock
BH
Toh
From the Cardiovascular Disease Program, Biomedicine Discovery Institute (C.T.C., C.G.S., M.L., D.F., M.M.K., H.D., H.A.K., S.M.K., C.V.L., A.V., C.S.S., G.R.D.), Department of Pharmacology (C.T.C., C.G.S., M.L., D.F., H.D., H.A.K., S.M.K., C.V.L., A.V., C.S.S., G.R.D.), Department of Surgery, Monash Health (C.G.S., G.R.D.), Department of Physiology (M.M.K.), Australian Regenerative Medicine Institute (E.S.), and Centre for Inflammatory Diseases, Department of Medicine, Southern Clinical School (P.T., B.-H.T.), Monash University, Clayton Victoria, Australia; Atherothrombosis and Vascular Laboratory (K.P.) and Vascular Biology and Atherosclerosis Laboratory (T.S.K., A.B.), Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia; British Heart Foundation Centre for Excellence, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom (T.J.G.); and Department of Internal Medicine, Jagiellonian University, Cracow, Poland (T.J.G).
Alexander
A
Bobik
From the Cardiovascular Disease Program, Biomedicine Discovery Institute (C.T.C., C.G.S., M.L., D.F., M.M.K., H.D., H.A.K., S.M.K., C.V.L., A.V., C.S.S., G.R.D.), Department of Pharmacology (C.T.C., C.G.S., M.L., D.F., H.D., H.A.K., S.M.K., C.V.L., A.V., C.S.S., G.R.D.), Department of Surgery, Monash Health (C.G.S., G.R.D.), Department of Physiology (M.M.K.), Australian Regenerative Medicine Institute (E.S.), and Centre for Inflammatory Diseases, Department of Medicine, Southern Clinical School (P.T., B.-H.T.), Monash University, Clayton Victoria, Australia; Atherothrombosis and Vascular Laboratory (K.P.) and Vascular Biology and Atherosclerosis Laboratory (T.S.K., A.B.), Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia; British Heart Foundation Centre for Excellence, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom (T.J.G.); and Department of Internal Medicine, Jagiellonian University, Cracow, Poland (T.J.G). Grant.Drummond@monash.edu.
Grant R
GR
Drummond
D019264:Adoptive Transfer; D000804:Angiotensin II / Q000009:adverse effects*; D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000494:pharmacology; D018951:Antigens, CD20 / Q000276:immunology; D053265:B-Cell Activation Factor Receptor / Q000172:deficiency / Q000235:genetics / Q000378:metabolism; D001402:B-Lymphocytes / Q000187:drug effects / Q000473:pathology* / Q000502:physiology*; D049109:Cell Proliferation; D004195:Disease Models, Animal; D006973:Hypertension / Q000139:chemically induced* / Q000378:metabolism / Q000503:physiopathology*; D007074:Immunoglobulin G / Q000378:metabolism; D051379:Mice; D018345:Mice, Knockout; D013154:Spleen / Q000473:pathology; D016212:Transforming Growth Factor beta / Q000378:metabolism; D059289:Vascular Stiffness / Q000502:physiology*
D000888:Antibodies, Anti-Idiotypic; D018951:Antigens, CD20; D053265:B-Cell Activation Factor Receptor; D007074:Immunoglobulin G; D016212:Transforming Growth Factor beta; D000804:Angiotensin II
hypertension; immune system; immunology; inflammation; lymphocytes